20440T

13/15

投票結果◉◉推奨文「肝切除後・穿刺局所療法後と同様，初発時の超高危険群に対するサーベイランスに準じた腫瘍マーカーと画像検査の併用による経過観察を推奨する」について委員による投票の結果，強い推奨となった。　肝移植後にも肝切除後・穿刺局所療法後と同様，最低でも超高危険群に準じた厳密な経過観察が必要である。■参考文献 1） Liu D, Chan AC, Fong DY, Lo CM, Khong PL. Evidence—based surveillance imaging schedule after liver transplantation for hepatocellular carcinoma recurrence. Transplantation 2017; 101:107—11. PMID: 28009758行うことを強く推奨する100％（25名）100％（25名）行うことを弱く推奨する0％（0名）0％（0名）行わないことを弱く推奨する0％（0名） 2） Vivarelli M, Cucchetti A, Piscaglia F, Barba GL, Bolondi L, Cavallari A, et al. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl 2005; 11: 497—503. PMID: 15838913 3） Vivarelli M, Cucchetti A, La Barba G, Ravaioli M, Gaudio MD, Lauro A, et al. Liver transplanta-tion for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg 2008; 248: 857—62. PMID: 18948815 4） Vivarelli M, Dazzi A, Zanello M, Cucchetti A, Cescon M, Ravaioli M, et al. Effect of different immunosuppressive schedules on recurrence—free survival after liver transplantation for hepa-tocellular carcinoma. Transplantation 2010; 89: 227—31. PMID: 20098287 5） Kohli V, Singhal A, Elliott L, Jalil S. Antiviral therapy for recurrent hepatitis C reduces recur-rence of hepatocellular carcinoma following liver transplantation. Transpl Int 2012; 25: 192—200. PMID: 22151471 6） Rodríguez—Perálvarez M, Tsochatzis E, Naveas MC, García—Caparrós C, O’Beirne J, Poyato—González A, et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol 2013; 59: 1193—9. PMID: 23867318 7） Kornberg A, Witt U, Kornberg J, Friess H, Thrum K. Treating ischaemia—reperfusion injury with prostaglandin E1 reduces the risk of early hepatocellular carcinoma recurrence following liver transplantation. Aliment Pharmacol Ther 2015; 42: 1101—10. PMID: 26282466 8） Zhang Q, Chen H, Li Q, Zang Y, Chen X, Zou W, et al. Combination adjuvant chemotherapy with oxaliplatin, 5—fluorouracil and leucovorin after liver transplantation for hepatocellular carci-noma: a preliminary open—label study. Invest New Drugs 2011; 29: 1360—9. PMID: 21809025 9） Geissler EK, Schnitzbauer AA, Zülke C, Lamby PE, Proneth A, Duvoux C, et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open—label phase 3 trial. Transplantation 2016; 100: 116—25. PMID: 26555945 10） Rodríguez—Perálvarez M, Guerrero M, Barrera L, Ferrín G, Álamo JM, Ayllón MD, et al. Impact of early initiated everolimus on the recurrence of hepatocellular carcinoma after liver trans-plantation. Transplantation 2018; 102: 2056—64. PMID: 29757893 11） Xu SL, Zhang YC, Wang GY, Yang Q, Liu B, Zhang J, et al. Survival analysis of sirolimus—based immunosuppression in liver transplantation in patients with hepatocellular carcinoma. Clin Res ＊＊＊CQ 50277行わないことを強く推奨する0％（0名）投票総数：25名